ZNTL Zentalis Pharmaceuticals Inc

$ZNTL Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract "The published abstract reports results for OS, a secondary endpoint of DENALI Part 1b in patients with platinum-resistant ovarian cancer (PROC), from an interim analysis. As of the September 2, 2025 data cutoff: In the Cyclin E1-positive subgroup (n=48): median OS of 15.8 months (95% CI, 8.7–17.8); In the Cyclin E1-negative subgroup (n=46): median OS of 7.5 months (95% CI, 5.8–12.3)"

$ZNTL posted OS data for azenosertib in ovarian cancer, median OS 15.8 mo in Cyclin E1-positive patients.

$ZNTL (Zentalis, San Diego developer of oral ovarian cancer drug azenosertib): in an interim DENALI Part 1b look, Cyclin E1-negative patients had median survival of 7.5 months on the drug vs 15.8 months for Cyclin E1-positive. Market value ~$152.7M at $2.13 (16:00 ET Oct 16, 2026, pre-offering share count) vs $174.6M cash and investments at June 30, before a ~$75.1M net August stock sale. Caveats: Cyclin E1 status set retrospectively, data cut Sept 2, 2025, judged vs historical chemo, not a control arm. Full talk at ESMO Oct 23.

$ZNTL i get the delay caused this downward pressure but this seems way overboard. They delay was to provide a comphrensive side by side trail to prove this therapy is superior over the only other therapy which is chemo. Gives us all an opportunity to buy

$ZNTL On October 5, 2026, Leerink Partners announced it has assumed coverage on Zentalis Pharmaceuticals ZNTL and upgraded its rating to Outperform. The analyst, Asthika Goonewardene, raised the price target from $4.00 to $8.00, representing a significant increase of 100%.

$ZNTL nice to see a pop. but going to wait for $2.50. its been close. a good few red market days and it will get there

$ZNTL man this tempting to load up but it keeps falling! with no real catalyst for 5-6 months will we see $2 again? it could 3-4x from there

$ZNTL Leerink raised its target to USD 8 for Zentalis Pharmaceuticals stock - Clinical data presentations are scheduled for October 23, 2026, and October 26, 2026.

$ZNTL They say you shouldn't try to catch a falling knife. But doesn't it just seem like you could catch this one right before it hits the ground? 😆

Latest company news, October 18, 2026: Zentalis published DENALI Part 1b interim overall-survival data in its ESMO abstract: median OS 15.8 months in the Cyclin E1-positive subgroup (n=48) vs 7.5 months in the negative one (n=46). Single-arm study. Zentalis Pharmaceuticals $ZNTL: Azenosertib And Catalysts Deeper dive in our hub. Not investment advice.

$ZNTL 🏥 Zentalis Pharmaceuticals announced first overall survival data from an interim analysis of the DENALI Part 1b (GOG-3066) study, showing median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy, published in an ESMO Congress 2026 abstract. Curated for market relevance

$ZNTL the ceo of ZNTL is a woman. Nuff said. She is not capable of any leadership and is allowing shareholder value to be absolutely destroyed

$ZNTL this keeps tracing back to $2.50s something tells me one big red market day and this may test lower . Probably would see tons of buying low $2S like early in the year

$ZNTL Btw whoever said it was right .. the data delay is hurting Zentalis short term … Its a 2027 event now …

$ZNTL dates according to Perplexity. October 2026 Denali 1 First half 2027 Denali 2 All goes well .. Pdufa filing 2nd half 2027.